Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Screening cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cancer screening method
InactiveUS20080311570A1Accurate screening resultEasy diagnosisMicrobiological testing/measurementFermentationScreening cancerScreening method
A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.
Owner:NAT DEFENSE MEDICAL CENT
Methods for enhancing antibody-induced cell lysis and treating cancer
InactiveUS7534772B2Low levelMicrobiological testing/measurementGenetic material ingredientsScreening cancerCancer prevention
The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.
Owner:IOWA RES FOUND UNIV OF +1
Biological chips of surface plasma resonating biological sensor, preparation and application
The invention relates to a cell surface receptor biochip based on a surface plasmon resonance biosensor, a preparation method and application thereof. The biochip is characterized in that the chip is provided with a gold surface coating at a glass substrate and the gold surface is fixed with a sephadex layer which is fixed with the monoclonal antibody of the Beta subunit of the receptors of anti para-insulin and surface receptors are fixed by antibody capture. The preparation method includes that the monoclonal antibody of the Beta subunit of the receptors of anti para-insulin adopts the method of antibody capture and is fixed on the surface of CM5 chip based on the surface plasmon resonance biosensor, so as to produce the protein chip of para-insulin receptors which is applicable to the mutual action between IGF-1R and IRS-1, SHC, PI3K or GRB2 and hopeful to be applied to screening cancer-fighting drugs.
Owner:SHANGHAI INST OF MICROSYSTEM & INFORMATION TECH CHINESE ACAD OF SCI +1
Method for Evaluating Physical Conditions Using Head Hair or Body Hair
InactiveUS20070258561A1Easy to handleEasy to implementMaterial analysis using wave/particle radiationX-ray spectral distribution measurementScreening cancerHair roots
It is intended to provide a method of improving dietary life or screening cancer which comprises measuring the content of an element in head hair or body hair, paying attention to the fact that the content of the element remains constant in healthy humans (i.e., homeostasis) and thus evaluating the physical conditions based on changes in the homeostasis. Namely, a method of evaluating the physical conditions whereby the physical conditions can be evaluated by measuring the content of an element in an arbitrary part of head hair or body hair. Although one's physical conditions change everyday, these changes are scarcely self-noticeable. Therefore, it is required to objectively indicate such changes in the physical conditions in numerical terms. Because of being solid, head hair or body hair can be easily handled. Thus, they are most suitable for analyzing the content of an element and enable large-scaled diagnosis at fixed intervals. This method of evaluating the physical conditions using head hair or body hair, whereby the content of an element at present can be measured by analyzing the hair root while its content of the past can be measured by analyzing at an arbitrary part, is highly effective in evaluating the physical conditions.
Owner:CHIKAWA JUN ICHI
Application of cfDNA in non-invasive diagnosis of early breast cancer
ActiveCN111910004AAchieve early diagnosisNon-invasiveMicrobiological testing/measurementBiostatisticsScreening cancerEarly breast cancer
Application of cfDNA in non-invasive diagnosis of early breast cancer The present invention discloses an application of cfDNA in non-invasive diagnosis of early breast cancer, a cfDNA marker with relatively high sensitivity and specificity for diagnosing breast cancer and a product for diagnosing breast cancer prepared based on the marker, and at the same time a method for screening cancer markers.
Owner:WENZHOU INST UNIV OF CHINESE ACAD OF SCI +3
Targeting qualitative and quantitative metabonomic analysis method used for screening cancer biomarkers based on LC-MS/MS technology
The invention relates to a targeting qualitative and quantitative metabonomic technical analysis method used for screening cancer biomarkers based on the LC-MS / MS technology. The method is characterized in that a structure prediction function of multi-reaction monitoring-dependent information acquisition-enhanced daughter ion detection on correlative metabolites and a structure identification function of a high-resolution mass spectrum are predicted by fully utilizing a multi-reaction monitoring quantitation function of the high performance liquid-tandem mass spectrum, and the analysis methodsuitable for screening biomarkers of various cancers is formed. The method has the advantages of high flux, good stability and high adaptability, and improves sensitivity and accuracy of screening andfinding of metabonomic biomarkers.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Cancer screening method
InactiveUS8048634B2The effect is accurateMicrobiological testing/measurementScreening cancerScreening method
Owner:NAT DEFENSE MEDICAL CENT
Method for detecting cancer of stomach prognosis and staging blood serum protein
InactiveCN101451975AQuick checkEasy to detectMaterial analysis by electric/magnetic meansBiological testingSerum protein profileScreening cancer
The invention provides a method of detecting cancer of stomach, judging prognosis and stage in blood serum, comprising: (1) mensurating a proteid icon of blood serum sample between tumor patients and healthy persons through a surface enhanced laser desorption / ionization-time of flight mass spectrometry (SELDI); (2) screening out corresponding tumor marker and building a detecting model for analyzing detection combined with a method of bioinformatics. The inventive method provides a serum protein profiling for conveniently and efficiently detecting cancer of stomach, increases efficiency of screening cancer of stomach, saves medical cost. Meanwhile for the cancer of stomach patients with confirmed diagnosis, the invention provides a serology method of differentiating bad prognosis and late stage, for guiding patients for treatment. At the same time, the invention provides markers for further research.
Owner:ZHEJIANG UNIV
Cancer screening method
InactiveUS7820386B2Accurate screening resultEasy diagnosisMicrobiological testing/measurementFermentationScreening cancerScreening method
A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.
Owner:NAT DEFENSE MEDICAL CENT
Intelligent cervical cancer cell detection method based on deep learning
ActiveCN112365471AAccurate classificationEasy to masterImage enhancementImage analysisScreening cancerCancer cell
The invention discloses an intelligent cervical cancer cell detection method based on deep learning. The invention relates to classification of cell nucleuses by a deep learning method. The inventionaims to solve the problems of low cancer cell detection accuracy, long consumed time and the like in the existing traditional diagnosis mode. In order to solve the problem, the invention provides an intelligent cervical cancer cell screening method based on deep learning. The method comprises the following specific steps: 1, preparing data; 2, carrying out cell nucleus segmentation; 3, carrying out cell nucleus classification; and 4, screening cancer cells. In the cell nucleus classification part, data expansion and category subdivision are carried out on the data by using an active learning method; on the model, ResNeSt is taken as a basic model, doctor diagnosis experience is introduced, and a more accurate model is trained under the combined action of diagnosis index extraction. Experiments show that the accuracy of the cell nucleus classification method is higher than that of an original model, and in addition, the invention further provides a more effective data preparation methodfor expanding data and subdividing categories. The method is applied to the field of medical image classification.
Owner:HARBIN UNIV OF SCI & TECH
Novel use of ubiquitin c-terminal hydrolase-l1
InactiveCN101316605AInhibit cancer metastasisPeptide/protein ingredientsMicrobiological testing/measurementScreening cancerUbiquitin C
Owner:EWHA UNIV IND COLLABORATION FOUND +1
Polyclonal antibodies against fibrinogen degradation products and associated methods of production and use
InactiveUS20080118936A1Increase production levelsReduce effortSerum immunoglobulinsBiological material analysisScreening cancerSerum ige
Monospecific polyclonal fibrinogen degradation product antibodies, their method of use, the methods to detect cancer and for monitoring the progress of anticancer treatment by immunochemically measuring the quantity of serum FDP in serum are disclosed. The present invention teaches that monospecific polyclonal FDP antibodies that bind to human fibrinogen degradation products (“FDP”) can be obtained by inoculating a laboratory animal with human FDP or human FDP derivatives to induce the production in the inoculated laboratory animal of at least one monospecific polyclonal antibody that binds to human FDP and isolating the monospecific polyclonal antibody. By generating anti-serum to FDP from immunogens and purifying said immunogens using affinity chromatography, increased levels of production of FDP antibodies over the prior art are achieved. A method for screening cancer is disclosed comprising contacting biological sample obtained from a patient with at least one monospecific polyclonal FDP antibody that binds to mammalian FDP. A method is also disclosed for producing a quantitative enzyme linked immunosorbent assay (ELISA) for serum FDP by using monospecific polyclonal antibodies that bind to human FDP.
Owner:NGO THAT T
Method for detecting telomerase activity in liquid biopsy
InactiveCN109266726AHigh affinityGuaranteed extraction efficiencyMicrobiological testing/measurementTelomeraseScreening cancer
The invention discloses a method for detecting telomerase activity in liquid biopsy, which utilizes avidin-labeled magnetic beads to adsorb and label the extended product with biotin after screening cancer cells, thereby achieving the effect of removing proteins and other impurities in the liquid. Compared with the prior art, the invention has the advantages that: At that end of screen cancer cell, 1*TRAP system, biotin-labeled TS primer, dNTP, RII were added. After the cells were disrupted by ultrasound, the telomerase activity was elongated by 30 DEG C water bath for 30 minutes, and then magnetic beads were added to remove the liquid. Finally, tRAP PCR reaction system was added to carry out PCR reaction with magnetic beads. This method can completely remove the influence of protein and other impurities, and the magnetic beads labeled with avidin have super affinity with the target product labeled with biotin, which can ensure the efficiency of extraction.
Owner:江苏凯强医学检验有限公司
Cancer screening and diagnosis method via staining quantification of cellular DNA by fluorescent dye DAPI
InactiveCN109946278AShort dyeing timeEasy to operatePreparing sample for investigationFluorescence/phosphorescenceScreening cancerCancer cell
The invention discloses a cancer screening and diagnosis method via staining quantification of cellular DNA by a fluorescent dye DAPI. According to the method, cell nucleuses in cell smears or cells and tissue sections are stained with DAPI as a dye, pictures are taken under a fluorescence microscope, and the DNA in each nucleus is relatively quantified according to the fluorescence intensity of each nucleus. Cells with abnormal DNA content (non-integer ploidy or ploidy number being greater than 4.5 or above) are suspected cancer cells. The number and morphology of the suspected cancer cells can be used for cancer screening and diagnosis. The dyeing method provided by the invention has the advantages of short dyeing time, simple operation and accurate quantification, is wide in application, can quantify the DNA of cells in cell smears, tissue sections and cultured cells, and can be used for screening cancer samples.
Owner:贺权源
Test composition for screening cancers
InactiveUS20150337386A1Nucleotide librariesMicrobiological testing/measurementScreening cancerNucleotide
Owner:ISTAT BIOMEDICAL
Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
InactiveUS20150252432A1High incidenceHigh mortality rateCompound screeningApoptosis detectionScreening cancerScreening method
A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.
Owner:GEORGE WASHINGTON UNIVERSITY
Novel use of ubiquitin c-terminal hydrolase-l1
InactiveUS20090208508A1Cancer metastasis can be suppressedPeptide/protein ingredientsImmunoglobulinsScreening cancerLymphatic Spread
The present invention relates to a composition for diagnosing cancer metastasis comprising Ubiquitin C-terminal hydrolase-L1 (UCH-L1), a use of UCH-L1 for diagnosing cancer metastasis and a method for diagnosing cancer metastasis using the same; a composition for suppressing cancer metastasis comprising an inhibitor of UCH-L1, a use of an inhibitor of UCH-L1 for suppressing cancer metastasis and a method of suppressing cancer metastasis using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 protein, a use of UCH-L1 protein for screening a cancer metastasis inhibitor and a method of screening cancer metastasis inhibitor using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 gene, a use of UCH-L1 gene for screening a cancer metastasis inhibitor, a method of screening cancer metastasis inhibitor using the same.UCH-L1 is a key molecule to modulate cell migration including the cancer invasion according to their expressing level. Thus, the monoclonal and polyclonal antibodies and the substrate of UCH-L1 can be used for diagnosis of cancer metastasis.Also, the cancer metastasis can be suppressed by inhibiting of the expression of UCH-L1 or activity of the enzyme, thus we can screen and develop an inhibitor of UCH-L1 and use it as an adjuvant drug for anticancer therapy.
Owner:EWHA UNIV IND COLLABORATION FOUND +1
Novel circulating tumor cell identification technology
PendingCN111812071ASolve bottlenecksEasy to operateBiological testingFluorescence/phosphorescenceScreening cancerProtein markers
The invention provides an identification technology of a novel circulating tumor cell (CTC). The identification technology is used for identifying the CTC. The method is characterized in that body fluid (such as peripheral blood) of a tumor patient is subjected to standard sampling, transportation and storage, sample pretreatment, CTC enrichment and separation on a microfiltration film, cell immobilization, cell silver staining and immunofluorescence in-situ detection, whether the cells are tumor cells or not is determined according to the karyoplasm proportion, the irregular nucleolus characteristics and the number, and finally the organ tissue source of CTC in blood is determined through fluorescence immunoassay of tissue and organ specific protein markers. According to the method, CTC is subjected to in-situ microscopic examination, tumor cells are detected, organ tissue sources of circulating tumor cells are determined, a long-term problem that CTC morphological identification lacks a believable method is solved, and establishment of a unified standard for CTC detection is facilitated. The method has advantages of being easy to operate, good in repeatability, high in stabilityand the like, and can be used for early screening of tumor high-risk groups, curative effect evaluation of cancer patients and recurrence monitoring.
Owner:BLOOD TRASFUSION INST CHINESE ACAD OF MEDICAL SCI
Method for screening cancer therapeutic agent using galectin-3, GSK-3β, and fascin-1
InactiveUS9068231B2Increase in motilityControl changesCompound screeningApoptosis detectionScreening cancerFascin
Owner:NAT CANCER CENT
Method for negatively screening cancer cell by using biomagnetic beads in liquid biopsy
InactiveCN109266612ANo false positive resultsCell dissociation methodsTumor/cancer cellsScreening cancerTelomerase
The invention discloses a method for negatively screening cancer cells by using biomagnetic beads in liquid biopsy, which comprises the following steps: (a) centrifuging a sample through a density gradient to process the sample, and the sample is taken from the body fluid of a cancer patient to detect the processed sample, that is a candidate sample, and relates to the technical field of biological detection. The method utilizes biomagnetic beads to negatively screen cancer cells in liquid biopsy, two kinds of biomagnetic beads were used to adsorb the immune cells which could affect the detection of telomerase activity, so that the false positive results could not be found in the experiment, and other cells were still in the sample through negative screening, so that the false negative results could not be found in the experiment.
Owner:江苏凯强医学检验有限公司
Method for screening cancer
ActiveUS10221458B2Promote resultsThe result is accurateMicrobiological testing/measurementSYT9Screening cancer
Owner:NAT DEFENSE MEDICAL CENT
Two-well immunoassay lateral flow test card
Owner:天津东亚生物技术有限公司
Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial
InactiveUS20160334389A1Small sizeMinimize changesCompound screeningApoptosis detectionScreening cancerCancer prevention
The present invention relates to a method for screening an anticancer agent or a cancer preventive agent, comprising the steps of: (a) isolating mutant luterial or normal luterial from a body fluid extracted from a patient or a normal person; (b) treating the isolated mutant luterial with anticancer agent candidates or cancer preventive agent candidates; and (c) either selecting, as the anticancer agent, a candidate that reduces the size or changes the shape or increases the mobility of the mutant luterial, compared to the control mutant luterial upon treatment with the candidate, or selecting, as the cancer preventive agent, a candidate that suppresses the increase in size, minimizes the change in shape or maintains the mobility of luterial, compared to the control luterial, upon treatment with the candidate.
Owner:CHOI WON CHEOL +3
Single cell RNA sequencing
PendingCN114364814AMicrobiological testing/measurementMaterial analysisScreening cancerSingle cell transcriptome
The invention relates to a single cell transcriptome sequencing (scRNA-seq) technology which is applied to primary cells or cell lines for high-throughput drug screening and new application of old drugs. The present invention relates to an analytical method for cell-based drug screening, comprising the steps of: culturing a population of cells in a culture environment; exposing the cell population to a drug substance, wherein a clear time monitoring point and a concentration monitoring point of the drug substance are set; after being exposed in a drug substance, a single cell library is formed; performing single-cell RNA sequencing of the single-cell library on a plurality of genes of the independently sorted cells in the cell library; and performing a bioinformatics analysis to determine differentially expressed genes. Furthermore, the present invention relates to the use of an analytical method for cell-based drug screening in which differentially expressed genes are potential marker genes and are used for screening cancer drugs.
Owner:SINGLERON NANJING BIOTECHNOLOGIES LTD
Method for screening cancer
InactiveUS20190136330A1Promote resultsThe result is accurateMicrobiological testing/measurementScreening cancerSYT9
Owner:NAT DEFENSE MEDICAL CENT
A method of cancer screening
ActiveCN101570779BIncreased sensitivityStrong specificityMicrobiological testing/measurementScreening cancerBisulfite sequencing
A cancer screening method comprises the following steps: (1) a tested body is provided; (2) the methylation state of a CpG sequence of at least one target gene of genome DNA of the tested body is detected, wherein the target gene comprises SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; (3), whether the tested body has a cancer or a precancerous lesion is judged according to the methylation state of the target gene. A methylation state detection method adopts MSP (methylation-specific PCR), QMSP (quantitative methylation-specific PCR), BS (bisulfite sequencing), microarrays, mass spectrometer, DHPLC (denaturing high-performance liquid chromatography) and the like.
Owner:赖鸿政
Cancer marker screening method based on methylation enhanced gene expression (MEGE)
PendingCN114075605AImprove the detection rateImprove throughputMicrobiological testing/measurementScreening cancerExpression gene
The invention provides a cancer marker screening method, which comprises the following steps: screening cancer markers based on tissue gene expression level differences between a target cancer and other cancers, and tissue gene expression level differences and methylation level differences between the target cancer and normal tissues, wherein the gene expression level difference between the target cancer and other cancer tissues indicates that the gene expression level of the marker in the target cancer is obviously higher than that of the marker in other cancer tissues, the gene expression level difference between the target cancer and the normal tissue indicates that the gene expression level of the marker in the target cancer is obviously higher than that in the normal tissue, and the methylation level difference between the target cancer and the normal tissue indicates that the methylation level of the marker in the target cancer is obviously higher than that of the marker in the normal tissue. The method disclosed by the invention is expected to be complementary with a conventional methylation marker, well improves the cancer detection rate, and has the advantages of accuracy, rapidness and high throughput.
Owner:BIOCHAIN BEIJING SCI & TECH
A kit for screening cancer brain metastases
ActiveCN106916900BHigh risk of transferHigh riskMicrobiological testing/measurementScreening cancerAids diagnostics
Owner:成都医学院第一附属医院
Search for cancer markers by a novel screening method
InactiveUS20050106624A1Efficient screeningTumor rejection antigen precursorsTumor specific antigensScreening cancerSerum free
The present invention relates to a method of concentrating low molecular weight peptides in the supernatant of serum-free cultured cells, said method comprising allowing the peptides to bind to a strong cation exchanger under an acid condition, and eluting them under an alkali condition to concentrate the peptide. Furthermore, peptides having the amino acid sequence as set forth in SEQ ID NO: 1 or 2, and a method of screening cancer markers using antibody to these peptides, are disclosed.
Owner:JAPAN REPRESENTED BY DIRECTOR GEN OF AGENCY OF NAT CANCER CENT +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com